EBITDA: Income before interest, taxes, depreciation and amortization.
Rani Therapeutics Holdings, Inc. (RANI) had EBITDA of $-37.48M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$1.63M |
|
$-29.67M |
|
-- |
|
$1.63M |
|
$39.94M |
|
$-38.31M |
|
$-2.64M |
|
$-40.95M |
|
$-40.95M |
|
$-40.95M |
|
$-40.95M |
|
$-40.95M |
|
$-40.95M |
|
$-38.31M |
|
|
EBITDA |
$-37.48M |
66.14M |
|
66.14M |
|
$-0.45 |
|
$-0.45 |
|
| Balance Sheet Financials | |
$53.32M |
|
$0.74M |
|
$5.30M |
|
$58.62M |
|
$12.67M |
|
-- |
|
$4.44M |
|
$17.11M |
|
$41.51M |
|
$41.51M |
|
$41.51M |
|
121.59M |
|
| Cash Flow Statement Financials | |
$-18.71M |
|
$-7.03M |
|
$40.30M |
|
$4.26M |
|
$18.82M |
|
$14.56M |
|
$11.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.21 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-2345.99% |
|
-2345.99% |
|
-2295.22% |
|
-2507.66% |
|
-1817.09% |
|
$-18.80M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
0.80 |
|
456.42 |
|
-98.65% |
|
-98.65% |
|
-69.86% |
|
-98.65% |
|
$0.34 |
|
$-0.28 |
|
$-0.28 |
|